Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$3.98
▼ $0.04 (-0.9%)
Market data updated: 09/22 06:37 PM
Fundamentals updated: 09/22/2026
News analyzed: 09/22/2026
Market Cap
$380.21M
Day Range
$3.76 - $4.01
52-Week Range
$2.74 - $8.59
Beta
—
Next Earnings
02.11.2026
Support
$2.74
Resistance
$6.43
MYGN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-49.3% (1Y)
Strengths: 16/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
Operating margin
Operating margin: -47.0% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
51
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
11d ago · $3.36
Evidence: FOMO score jumped from 0 to 30 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
32
Quality
63
Value
50
Momentum
72
Risk
46
Sentiment
44
Fundamental
39
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Myriad Genetics has focused on its stock volatility and analyst downgrades, with no substantive company-specific developments. Analysts like UBS and Piper Sandler have adjusted or lowered price targets, citing profitability concerns, while headlines highlight share declines following downgrades. The limited coverage lacks detailed operational or financial updates, instead emphasizing market sentiment and analyst reactions.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Myriad Genetics, Inc.. News trend score: 44. Reason: 5 of the last 20 articles are negative, versus 4 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
43
🎯 Conviction (vs. Emotion)
40
Psychology
62
Fundamentals
39
Technical
72
Valuation
50
The price rise has far outpaced the actual improvement in fundamental data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Price, sentiment, and valuation keep confirming each other upward while the actual fundamentals deteriorate.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-24%
Market Narrative
65
Fundamental Reality
40
Narrative Gap
+25
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
The market’s extreme loss aversion (96) suggests traders are prioritizing avoiding further declines over potential recovery, amplified by a 33% drop over three months. Herding (69) indicates passive alignment with peers, while muted panic (29) and absent FOMO/Euphoria imply a cautious, risk-averse stance. The key question is whether the narrative gap (-14) reflects an overlooked catalyst or if traders are correctly discounting fundamentals. Low volume and subdued volatility may signal hesitation rather than urgency.
Updated: 09/09/2026, 02:43 PM
What could change this?
👥 What the crowd believes
"Piper Sandler Downgrades Myriad Genetics to Underweight From Overweight (MT Newswires #12)"
"Myriad Genetics Shares Fall After Piper Sandler Downgrade (MT Newswires #8)"
"Stocks making big moves yesterday: Myriad Genetics... (StockStory #6)"
"Its Profitability Problem Just Got Worse (Barrons.com #9)"
🧠 Market Brain events driving this
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 99/100
🔴 Weakest match
Samuel Armstrong Nelson — 14/100
🗣️ Why do they disagree?
The stark divide in verdicts for MYGN reflects deep methodological disagreements about risk, timing, and valuation. Defensive investors like Benjamin Graham and Charles Mackay see strong fundamentals and no signs of speculative excess, scoring near-perfectly, while their enterprising counterpart—who embraces deeper discounts—still rates it highly but with a more aggressive lens. Meanwhile, cycle-focused thinkers like Howard Marks (Market Cycle) and Samuel Nelson view the stock as favorably positioned within broader market phases, contrasting sharply with trend-followers like Jesse Livermore, who dismiss it outright due to perceived downtrend alignment. Efficiency skeptics like Malkiel/Bogle and Lynch/Fisher reject it as either unconvincing or lacking growth quality, while Veblen’s consumerist critique flags it as a speculative play. The split underscores whether MYGN’s risks are priced fairly (Marks, Schwager) or whether its flaws—liquidity concerns, trend weakness, or speculative appeal—override its strengths.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 99
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 87
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 81
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 81
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 78
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 74
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 71
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 56
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 51
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 47
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 40
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 38
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 32
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 29
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 14
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 284 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 3 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
69.9%
Operating Margin
-47.0%
Net Margin
-44.4%
EBITDA Margin
-40.4%
ROE
-99.4%
ROA
-51.8%
ROIC
—
EPS
-$3.95
Cash
$149.60M
Total Debt
$119.90M
Current Ratio
2.49
Debt/Equity
0.33
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$3.97
Tangible Book Value per Share (Tangible NAV)
$1.76
Sentiment based on basic keywords (not AI) — 4 positive, 11 neutral, 5 negative out of the last 20 articles.
Yahoo · 21.9.2026
Yahoo · 18.9.2026
Benzinga · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Benzinga · 16.9.2026
Yahoo · 15.9.2026
Benzinga · 11.9.2026
Benzinga · 10.9.2026
Benzinga · 9.9.2026
MT Newswires · 9.9.2026
Yahoo · 8.9.2026
StockStory · 8.9.2026
Yahoo · 4.9.2026
Zacks · 4.9.2026
Simply Wall St. · 3.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 2.9.2026
StockStory · 2.9.2026
Myriad Genetics, Inc. (MYGN) currently has a StockIQ AI score of 51/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
MYGN currently scores 51/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
MYGN's technical score is 72/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Debt/equity: 0.33; Current ratio: 2.49.
Based on the real signals StockIQ computed: Operating margin: -47.0% (negative); Net margin: -44.4% (negative); ATR: 6.3% of price.
StockIQ has no recorded dividend payment history for MYGN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Fox Jennifer Lynne | Tax Withholding in Shares | 3.9.2026 | 4,398 | -4,398 | $3.23 |
| Wheeler Benjamin Richard | Tax Withholding in Shares | 16.8.2026 | 8,761 | -8,761 | $3.03 |
| Raha Samraat S. | Grant/Award from Employer | 11.6.2026 | 3,542 | +3,542 | $3.94 |
| Donnelly Brian J | Grant/Award from Employer | 11.6.2026 | 5,000 | +5,000 | $3.94 |
| Raha Samraat S. | Grant/Award from Employer | 11.6.2026 | 1,068,083 | +3,542 | $3.94 |
| Donnelly Brian J | Grant/Award from Employer | 11.6.2026 | 573,363 | +5,000 | $3.94 |
| Kumar Rashmi | Open Market Sale | 8.6.2026 | 15,000 | -15,000 | $4.46 |
| Kumar Rashmi | Open Market Sale | 8.6.2026 | 171,889 | -15,000 | $4.46 |
| Kumar Rashmi | Grant/Award from Employer | 4.6.2026 | 59,701 | +59,701 | — |
| Newcomer Lee Nisley | Grant/Award from Employer | 4.6.2026 | 59,701 | +59,701 | — |
| Reitan Colleen F | Grant/Award from Employer | 4.6.2026 | 59,701 | +59,701 | — |
| Bisaro Paul | Grant/Award from Employer | 4.6.2026 | 59,701 | +59,701 | — |
| Phanstiel S. Louise | Grant/Award from Employer | 4.6.2026 | 59,701 | +59,701 | — |
| Skovronsky Daniel | Grant/Award from Employer | 4.6.2026 | 59,701 | +59,701 | — |
| Dreismann Heinrich | Grant/Award from Employer | 4.6.2026 | 59,701 | +59,701 | — |
| Davis Mark Steven | Grant/Award from Employer | 4.6.2026 | 59,701 | +59,701 | — |
| Bisaro Paul | Grant/Award from Employer | 4.6.2026 | 157,142 | +59,701 | — |
| Dreismann Heinrich | Grant/Award from Employer | 4.6.2026 | 231,145 | +59,701 | — |
| Phanstiel S. Louise | Grant/Award from Employer | 4.6.2026 | 341,652 | +59,701 | — |
| Reitan Colleen F | Grant/Award from Employer | 4.6.2026 | 152,030 | +59,701 | — |
| Skovronsky Daniel | Grant/Award from Employer | 4.6.2026 | 195,507 | +59,701 | — |
| Newcomer Lee Nisley | Grant/Award from Employer | 4.6.2026 | 191,842 | +59,701 | — |
| Kumar Rashmi | Grant/Award from Employer | 4.6.2026 | 186,889 | +59,701 | — |
| Davis Mark Steven | Grant/Award from Employer | 4.6.2026 | 106,665 | +59,701 | — |
| Jampa Raj | Grant/Award from Employer | 1.6.2026 | 251,889 | +251,889 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
7,844,099 shares short as of 2026-08-31 · vs. 8,496,114 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
23.7% of trading volume this week was short selling, vs. 46.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology